Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Investor Presentation (March 2022)
22 slides from Health X Platform's investor presentation, March 2022
Slide 1: Regulation 30 Intimation to Stock Exchanges
SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002 Date: 11-03-2022 To To The
Slide 2: Investor Presentation March 2022
Investor Presentation March 2022 SastaSundar Ventures Limited
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Quarterly Highlights
Quarterly Highlights 3
Slide 5: Q3 & 9MFY22 Financial Highlights
Q3 & 9MFY22 Financial Highlights Rs. In Crs Revenue from Operations Gross Profit 8.6% 5.8% 9.1% 6.6% 14.1% -16.5% 465.4 37.0 407.8 30.9 5.0% -28.7% 134.4 141.1 11.5 8.2 Q3FY21 Q3FY22 9MFY21 9MFY22 Q3FY21 Q3FY22 9MFY21 9MFY22 Revenue Gross Profit ✓ Revenue for Q3FY22 stood at Rs. 141.1 crs as compare
Slide 6: Q3 & 9M FY22 Consolidated Profit & Loss Statement
Q3 & 9M FY22 Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q3 FY22 Q3 FY21 Y-o-Y Q2 FY22 Q-o-Q 9M FY22 9M FY21 Y-o-Y Revenue from Operations 141.1 134.4 5.0% 154.7 -8.8% 465.4 407.8 14.1% Cost of Materials Consumed 132.9 122.9 144.6 434.5 370.8 Gross Profit 8.2 11.5 10.1 30.9 37.0 GP %
Slide 7: Management Comments
Management Comments Commenting on the results and performance for Q3 & 9M FY22, Mr. B.L. Mittal, Founder & Executive Chairman said: “This quarter is a landmark quarter in the history of the company, in which we successfully entered into partnership with Flipkart. The details of the terms & condition
Slide 8: Deal & Future Strategy
Deal & Future Strategy 7
Slide 9: Flipkart - SastaSundar Deal Structure
Flipkart - SastaSundar Deal Structure SastaSundar Ventures Ltd.(SVL) Mitsubishi Corporation & Rohto Pharmaceuticals 28% Shareholding 72% Shareholding SastaSundar Healthbuddy Limited (SHBL) Wholesale business to support Flipkart Health Pvt. Ltd Seller Pharmacy Network of SastaSundar.Com 100% 100% 24.
Slide 10: Financial Details of the Deal
Financial Details of the Deal • SML has received the amount of INR 372.00 crores from Flipkart Health Private Limited on account of allotment of equity shares of SML to Flipkart Health Private Limited; (holding 75.1% of Equity share capital of SML) • SHBL has also received INR 689.76 Crores from Fli
Slide 11: Future Macro Strategy: Focus & Growth
Future Macro Strategy Macro Strategy Focus & Growth ‘Digital Platform of Healthcare’ Pharmacy Wellness Diagnostic Develop Leverage Deliver 3T 2C 3C Team Cash Flow Customer Base Technology Customer Experience Capital Trust Community Wellbeing 10 Health & Happiness
Slide 12: Future Micro Strategy
Future Micro Strategy Micro Strategy B2C Platform B2B Platform Genu Path Labs • Expand & Grow network of Seller • Expand – PAN India, Accelerate • Expand Diagnostic Network in Eastern Pharmacies – PAN India growth India • Expand fulfilment capabilities – • Leverage scale to Maximise • Leverage consu
Slide 13: Historical Financial Highlights
Historical Financial Highlights 12
Slide 14: FY21 Financial Highlights
FY21 Financial Highlights Rs. In Crs Q4 Revenue Revenue from from Operations Operations Gross Profit Q3 Q2 4.5% 8.8% Q1 40% 178% 540 48 132 +14% 11 385 116 134 +30% 12 103 140 +52% 17 13 5 92 4 134 +81% 5 12 74 3 FY20 FY21 FY20 FY21 Gross Profit Revenue Revenue ✓ FY21 gross profit grew by 178% to Rs
Slide 15: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-21 Mar-20 Mar-19 Mar-18 Revenue from Operations 540.0 384.0 215.6 148.3 Cost of Materials Consumed 492.5 366.9 199.5 140.4 Gross Profit 47.5 17.1 16.1 7.9 GP % 8.8% 4.5% 7.5% 5.3% Employee Benefits Expense 29.1 28.4 23.4 16.2
Slide 16: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Equity & Liabilities (Rs. Crs) Mar-21 Mar-20 Mar-19 Mar-18 Assets (Rs. Crs) Mar-21 Mar-20 Mar-19 Mar-18 Equity Share Capital 31.8 31.8 31.8 31.8 Property, Plant and Equipment 57.3 60.2 62.7 64.8 Other Equity 197.6 214.4 168.6 171.3 Capital Work-in-Progress 0.1 0
Slide 17: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-21 Mar-20 Mar-19 Mar-18 Cash Flow from Operating Activities Profit before Tax (16.4) (57.6) (41.8) (12.4) Adjustment for Non-Operating Items (3.2) 4.8 7.8 5.4 Operating Profit before Working Capital Changes (19.6) (52.8) (34.0) (7
Slide 18: About Us
About Us 17
Slide 19: Backed by Globally Acclaimed Investors; Auditors
Backed by Globally Acclaimed Investors Mitsubishi Corporation Rohto Pharmaceutical Co., Ltd. At Business Level At Consolidated Level Auditors S.R. Batliboi & Co. LLP JKVS & Co. (a member firm of EY) 18 Health & Happiness
Slide 20: Experienced Board of Directors
Experienced Board of Directors ▪ FCA, FCS and FCM by education and has an experience of ▪ FCA by education and is a seasoned entrepreneur with more than 20 years working as an entrepreneur and a more than 20 years of demonstrated experience in social worker. scaling businesses from scratch. ▪ Areas
Slide 21: Join us for Prayers
Join us for Prayers 20 Health & Happiness
Slide 22: Thank You
Contact Information Thank You For Further Information, please contact: Company: Investor Relations Partner: Sastasundar Ventures Limited Orient Capital (a division of Link Group) CIN: L65993WB1989PLC047002 Payal Dave Mr. Pratap Singh – Company Secretary payal.dave@linkintime.co.in Email ID: p_singh@
Sastasundar Ventures — Investor Presentation (March 2022) on 6ix